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Abstract: Astrocytes play a major role in the pathogenesis of a range of neurodegenerative diseases,
including Alzheimer’s disease (AD), undergoing dramatic morphological and molecular changes
that can cause potentially both beneficial and detrimental effects. They comprise a heterogeneous
population, requiring a panel of specific phenotype markers to identify astrocyte subtypes, changes
in function and their relation to pathology. This study aimed to characterise expression of the
astrocyte marker N-myc downstream regulated gene 2 (NDRG2) in the ageing brain, investigate the
relationship between NDRG2 and a panel of astrocyte markers, and relate NDRG2 expression to
pathology. NDRG2 specifically immunolabelled the cell body and radiating processes of astrocytes
in the temporal cortex of the Cognitive Function and Ageing Study (CFAS) neuropathology cohort.
Expression of NDRG2 did not correlate with other astrocyte markers, including glial fibrillary acidic
protein (GFAP), excitatory amino acid transporter 2 (EAAT2) and glutamine synthetase (GS). NDRG2
showed a relationship to AT8+ neurofibrillary tangles (p = 0.001) and CD68+ microglia (p = 0.047),
but not β-amyloid plaques or astrocyte nuclear γH2AX immunoreactivity, a marker of DNA damage
response. These findings provide new insight into the astrocyte response to pathology in the ageing
brain, and suggest NDRG2 may be a potential target to modulate this response.
Keywords:N-mycdownstreamregulatedgene2 (NDRG2); astrocyte; ageingbrain; neurofibrillary tangles
1. Introduction
While much of the focus in dementia research has been on the neuron, other cell types are also
important. Astrocytes, the most abundant cell type in the central nervous system (CNS), play an
essential role in homeostasis, including neuronal support, synapse formation and function, maintenance
and metabolism [1,2]. They are classified into two major groups on the basis of their morphology and
anatomical location; the fibrous astrocytes of the white matter and the protoplasmic astrocytes of the
grey matter [2]. Astrocytes comprise a heterogeneous population [3,4], and different markers may
reflect different functional and structural aspects of the astrocyte, and their relationship to pathology.
Disruption of the normal astrocyte–neuronal interaction can lead to synaptic dysfunction and
contribute to cognitive impairment, as recently reviewed [5]. Production of pro-inflammatory cytokines
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and loss of neuronal support, such as neurotransmitter recycling, may contribute to neurodegeneration.
As part of the tripartite synapse, astrocytes regulate levels of neurotransmitters, including the excitatory
transmitter glutamate, and play a major role in preventing excitotoxicity caused by the accumulation of
excess glutamate [6,7]. Astrocytes remove excess glutamate from the extracellular space via excitatory
amino acid transporter 2 (EAAT2), and contain the enzyme glutamine synthetase (GS) which converts
glutamate to glutamine [8]. In addition to regulating neurotransmission, astrocytes are responsible for
providing metabolic support to neurons via the lactate shuttle [9].
Astrocytes react to a variety of CNS pathologies, including age-associated neurodegenerative
diseases such as Alzheimer’s disease (AD), by upregulating expression of the intermediate filament glial
fibrillary acidic protein (GFAP). Astrogliosis is one of the earliest changes in response to accumulating
AD pathology, β-amyloid (Aβ) plaques and neurofibrillary tangles (NFT) of hyperphosphorylated
tau [10]. This reactive astrogliosis is considered to play a neuroprotective role, protecting against
oxidative stress and promoting the clearance of Aβ [11].
N-myc downstream regulated gene 2 (NDRG2) mRNA and its corresponding protein are
principally expressed by protoplasmic and fibrous astrocytes throughout the brain [12–14]. Increased
expression of NDRG2 has been reported in neurodegenerative diseases, including AD [15,16],
frontotemporal lobar degeneration [17] and stroke [18]. The exact functions of NDRG2 are unknown
but it has been shown to have an inhibitory effect on tumour proliferation [19,20], reduce production
of reactive oxygen species and apoptosis [18], facilitate the hyperphosphorylation of tau [16], protect
blood–brain barrier integrity [21], and facilitate the uptake of glutamate by astrocytes [22].
The Cognitive Function and Ageing Neuropathology Study (CFANS) is a large scale, population
representative neuropathology cohort (>65 y) which contains the spectrum of age-associated
neurodegenerative pathologies. The study combined longitudinal assessment of cognitive function,
including Mini-Mental State Examination (MMSE), with a brain collection program to enable
neuropathological associations with cognitive impairment to be determined without preselection into
clinical groups [23]. The current study aimed to characterise the expression of NDRG2, investigate the
relationship between NDRG2 and a panel of astrocyte markers (GFAP, EAAT2, GS), and relate the
expression of NDRG2 to age-associated neurodegenerative pathology in the CFAS cohort.
2. Results
2.1. Comparison of the Immunoreactive Profile of NDRG2 with a Panel of Astrocyte Markers
NDRG2 exclusively immunolabelled the astrocyte cell body and radiating processes throughout the
cortex (Figure 1A). Both NDRG2 and EAAT2 (Figure 1B) extensively immunolabelled the distal delicate
processes of astrocytes, in comparison to antibodies against GFAP (Figure 1C) and GS (Figure 1D),
which predominantly stained astrocyte cell bodies and proximal cell processes. Quantitative assessment
of the immunoreactive profile of NDRG2, GFAP, GS, and EAAT2 across the cohort is shown in Table 1
and Figure 3A. Significant differences between these measures of astrocytes were detected (Friedman’s
p < 0.001). NDRG2 immunoreactivity did not correlate with either brain pH (rs = −0.067, p = 0.562) or
PMD (rs = 0.03, p = 0.79).
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Figure 1. Immunoreactive profiles observed with a panel of astrocyte markers. (A) N-myc downstream
regulated gene 2 (NDRG2 immunolabelled the astrocyte cell body (as indicated by the arrow) and
radiating processes (star). (B) excitatory amino acid transporter 2 (EAAT2) extensively immunolabelled
the extending processes (star) of astrocytes. Both (C) glial fibrillary acidic protein (GFAP) and
(D) glutamine synthetase (GS) predominantly stained astrocyte cell bodies and immediate cell processes
(arrow). Images are representative of the astrocyte immunolabelling profile observed in the temporal
cortex of 97 cases. Scale bar represents 50 µm.
Table 1. Comparison of the immunoreactive profile (% area immunoreactivity) of the astrocyte markers
NDRG2, GFAP, GS, and EAAT2 in the TCx of an ageing cohort.
Astrocyte Marker NDRG2 GFAP GS EAAT2
Mean (SD) 16.46 (11.75) 8.49 (8.98) 0.76 (0.84) 29.94 (26.87)
Median (IQR) 14.43 (7.25–22.1) 5.79 (2.12–11.55) 0.51 (0.23–0.99) 23.11 (8.42–43.61)
2.2. NDRG2 Does Not Correlate with the Expression of Other Astrocyte Markers
Expression of NDRG2 did not correlate with levels of GFAP (rs = −0.155, p = 0.134), EAAT2
(rs = −0.178, p = 0.091) or GS (rs = 0.085, p = 0.429). In contrast, GFAP negatively correlated with EAAT2
expression (rs = −0.249, p = 0.015) and EAAT2 expression correlated with GS expression (rs = 0.209,
p = 0.046) in the ageing brain. GFAP expression did not correlate with GS (rs = 0.147, p = 0.163).
2.3. Not All Astrocytes are NDRG2+
To assess if NDRG2 immunolabelled a greater proportion of astrocytes than the current standard
astrocyte marker GFAP, dual labelling was performed. While co-localisation of NDRG2 with GFAPwas
frequently observed, both NDRG2+/GFAP− and NDRG2−/GFAP+ astrocytes were detected (Figure 2).
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Figure 2. Colocalisation of NDRG2 with GFAP. (A–B) Colocalisation of NDRG2 (brown) with GFAP
(red) was frequently observed (as indicated by the star), however both NDRG2+/GFAP- (black arrow)
and NDRG2-/GFAP+ astrocytes (white arrow) were detected in the ageing temporal cortex. Scale bar
represents 100 µm in A and 50 µm in B.
2.4. NDRG2 Expression Correlates with Local Tau Pathology
NDRG2 expression did not correlate with Braak NFT stage, a measure of global AD pathology in
the ageing brain (JT p = 0.786) (Figure 3B), in contrast to both GFAP (JT p = 0.032) and GS (JT p = 0.017)
which showed a positive correlation.
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Figure 3. Assessment of NDRG2 expression in the ageing temporal cortex. (A) Significant differences
in the immunoreactive profile of a panel of astrocyte markers were detected (p < 0.001). (B) NDRG2
expression did not correlate with Braak stage, but did show a relationship to (C) local levels of tau
pathology (AT8) (rs = 0.335, p = 0.001), and (D) CD68
+ microglia (rs = 0.219, p = 0.047).
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As astrocytes respond to pathology in their immediate vicinity, we investigated the relationship
of NDRG2 to local measures of AD pathology, assessed by Aβ and AT8+% area immunoreactivity.
NDRG2 expression did not correlate with Aβ (rs = 0.154, p = 0.146), but showed a relationship to AT8
(rs = 0.335, p = 0.001) (Figure 3C). Dual immunolabelling confirmed increased expression of NDRG2 by
astrocytes in the vicinity of AT8+ neurones (Figure 4).
GS expression correlated with both Aβ (rs = 0.244, p = 0.02) and AT8 (rs = 0.242, p = 0.023). Neither
GFAP nor EAAT2 expression correlated with local levels of Aβ (GFAP rs = 0.128, p = 0.221; EAAT2
rs0.071, p = 0.503) or AT8 (GFAP rs = 0.163, p = 0.124; EAAT2 rs = −0.18, p = 0.087).
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Figure 4. NDRG2+ astrocytes associate with neurofibrillary tangles (NFT) in the ageing brain.
(A–B) NDRG2+ astrocytes (brown) associated with AT8 immunoreactivity (red), as indicated by the
black arrow. Scale bar represents 50 µm.
2.5. NDRG2 Expression Correlates with CD68 but not with Oxidative DNA Damage
To determine if NDRG2 associated with microglial reactivity we investigated the relationship
with CD68 and MHC II. NDRG2 correlated with CD68 (rs = 0.219, p = 0.047) (Figure 3D), but not MHC
II expression (rs = 0.164, p = 0.146) in the ageing brain. No other astrocyte marker correlated with
either CD68 (GFAP rs = 0.09, p = 0.409; EAAT2 rs = −0.051, p = 0.638; GS rs = 0.193, p = 0.078) or MHC
II (GFAP rs = −0.177, p = 0.109; EAAT2 rs = −0.013, p = 0.904; GS rs = 0.109, p = 0.331).
To determine if NDRG2 associated with oxidative stress we investigated their relationship with
γH2AX, a marker of oxidative DNA damage. NDRG2 did not correlate with astrocyte nuclear γH2AX
immunoreactivity (rs = 0.179, p = 0.089). Similarly, neither GFAP (rs = 0.025, p = 0.813), nor GS (rs = 0.14,
p = 0.183) correlated with γH2AX, however EAAT2 correlated with increased levels of astrocyte nuclear
γH2AX immunoreactivity (rs = 0.222, p = 0.033).
3. Discussion
NDRG2 is expressed at high levels in the brain, and plays a role in growth, differentiation and
development, and the stress response [24]. NDRG2 is upregulated in the hippocampus in AD in
post-mortem studies [15] and animal models [16]. However, in contrast to these studies which report
thatNDRG2 expression is associatedwith neurons, the current study demonstratesNDRG2 is exclusively
associated with astrocytes in the ageing brain and correlates with tau and microglial pathology.
NDRG2 was first identified in a normal human brain cDNA library in 2001 [25]. While some
studies report NDRG2 expression in pyramidal neurons, senile plaques and dystrophic neurons in the
hippocampus in AD [15], more recent studies investigating the expression of NDRG2 in a variety of
mammalian brains, including human, demonstrate that NDRG2 is a specific marker for astrocytes
and co-localises with the majority of known astrocyte markers [13,14]. In the current study, significant
differences in the immunoreactive profiles of the panel of astrocyte markers were detected and the
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patterns of staining varied greatly across the cohort, supporting the findings of a recent study comparing
NDRG2 expression with other astrocyte markers in different mouse cerebral regions [26]. Both GFAP
and GS predominantly labelled astrocyte cell bodies and immediate cell processes. However, as only
approximately 15% of the total astrocyte volume is GFAP+, the entire astrocyte domain is not fully
visualised [27]. In contrast, antibodies to NDRG2 and EAAT2 immunolabel the extending radiating
processes of astrocytes clearly demonstrating the extent of the astrocyte domain.
Levels of NDRG2 increase in AD transgenic mice (APP/PS1), and suppression of NDRG2 has
been shown to improve cognitive function in this model [28]. As the NDRG2+ distal processes of
astrocytes are in close proximity to synapses, this suggests a role in impairing synaptic transduction [13].
In contrast, NDRG2 deficiency has recently been shown to exacerbate long-term memory impairment
in this model of AD, suggesting a neuroprotective role for NDRG2 [29]. Recent studies have shown
that knockdown of NDRG2 significantly reduces tau phosphorylation in a human neuroblastoma cell
line overexpressing wild type APP695 [16]. Our data demonstrate that expression of NDRG2 positively
correlates with AT8+ tau pathology in the ageing brain; however, whether this is a mechanism actively
contributing to neuronal pathology or a response to neurodegeneration is currently unknown.
NDRG2 is an injury response gene that positively regulates early astrocyte activation and the
inflammatory response in a mouse model of cortical stab injury [30]. The reciprocal interactions between
microglia and astrocytes play a key role in the progression of AD [31]. In the current study NDRG2
did not correlate with expression levels of the other astrocyte markers but did correlate with CD68,
a lysosomal protein present in phagocytic microglia in the ageing brain. CD68+ microglia positively
associate with dementia, neuritic plaques and tangles in the ageing population [32]. Whether NDRG2+
astrocytes are linked to microglial pathology, or vice-versa, is unknown and whether these NDRG2+ glia
are adopting a neuroprotective or a neurotoxic phenotype needs to be determined. Additional studies
to interrogate the association with other microglial markers, including TREM−2, are also required.
NDRG2 is mainly expressed in the cytoplasm, however it has been shown to translocate to
the nucleus under stress conditions [33–35], and control astrocyte morphology via Rho-GTPase
signalling [36]. Oxidative stress and the associated DNA damage may directly impact astrocytes,
consequently modifying their normal function [37]. We previously reported a reduction in expression
of γH2AX by astrocytes associated with increasing levels of Alzheimer’s type pathology [38]. Here our
results demonstrate that the astrocyte DNA damage response does not correlate with NDRG2 but does
correlate with expression of EAAT2. Both γH2AX and EAAT2 were highest in cases with low levels of
AD pathology, and which may constitute a stress-response aimed at increasing glutamate uptake and
reducing neuronal excitotoxicity at the earliest stages of AD pathology.
Ageing population-representative neuropathology cohorts, such as CFAS, are a valuable resource
for investigating correlates of cellular pathology. A comprehensive panel of astrocytemarkers, including
NDRG2, is required to fully elucidate the complexity of the astrocyte response, providing a snapshot
of different aspects of astrocyte pathobiology and how they relate to age-related neurodegenerative
pathology. In the current study we demonstrate that NDRG2 is exclusively expressed by astrocytes,
and that levels of NDRG2 positively correlate with neurofibrillary tangles and CD68+ microglial
pathology in the temporal cortex of the CFAS cohort. Future studies are required to characterise the
interaction between NDRG2+ astrocytes, microglia and tangle pathobiology, andmay identify potential
therapeutic targets to modify the astrocyte phenotype.
4. Materials and Methods
4.1. Human CNS Cases
Human autopsy brain tissue was obtained from one centre (Cambridge, 97 cases) of the Cognitive
Function and Ageing Study (CFAS) [23,39], following multi-centre research ethics committee (REC)
approval (REC Reference number 15/SW/0246, 10 August 2015). Formalin-fixed lateral temporal cortex
samples (superior/middle temporal gyrus, Brodmann areas 22/21) of all cases in the subcohort were
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used to maintain the population-representative basis of the study. Neuropathological lesions were
previously assessed as part of the core CFAS neuropathology study using a modified protocol from the
Consortium to Establish a Registry of Alzheimer’s Disease (CERAD) [40] (wwws.cfas.ac.uk) and Braak
neurofibrillary tangle (NFT) staging [41]. The mean age of death was 85.6 years (SEM 7.4). The median
post-mortem delay was 17 h (interquartile range [IQR] 10–32 h) and brain pH 6.49 (IQR 6.25–6.75).
4.2. Immunohistochemistry
Immunohistochemistry was performed using a standard avidin-biotin complex (ABC) method.
Sections were deparaffinised, rehydrated to water and endogenous peroxidase activity quenched by
placing the sections in 0.3% H2O2/methanol for 20 min at room temperature (RT). Following pressure
cooker antigen retrieval in Access Super pH9.5 (Menarini Diagnostics, Wokingham, UK) and incubation
with 1.5% normal serum for 30 min at RT, the sections were incubated with primary antibody (Table 2).
To visualise antibody binding, the horse-radish peroxidase avidin biotin complex was used (Vectastain
Elite goat IgG kit, Vector Laboratories, Peterborough, UK) with 3,3′-diaminobenzidine (DAB) as the
chromagen (Vector Laboratories, UK; brown). Negative controls, either omission of the primary
antibody or goat isotype control, were included in every run.
Dual labelling experiments to visualise colocalisation of NDRG2 with neurofibrillary tangles or
GFAP were performed using a combined colour product method. Briefly, NDRG2 expression was
first visualised as described above. Sections were then incubated with the avidin-biotin blocking kit
(Vector Laboratories, UK), according to the manufacturer’s instructions. The tissue was incubated
overnight at 4 ◦C with either anti-AT8 (1:400) or anti-GFAP (1:1000), followed by biotinylated
secondary antibody, and visualised with the alkaline-phosphatase-conjugated avidin-biotin complex
and alkaline phosphatase substrate 1 (Vector Laboratories, UK, red). Every immuno-run included a
single-labelled section, which showed the same pattern and intensity of immunoreactivity as seen in
the double-labelling experiments.
Table 2. Antibody source and specificity.
Specificity Isotype Dilution Antigen Retrieval Supplier
AT8 (tau) mouse IgG1 1:400 PC, AS pH9.5 Endogen, UK
CD68 mouse IgG3κ 1:100 MW 10 min, TSC DakoCytomation, UK
EAAT2 (Glt-1) mouse IgG2A 1:20 PC, AS pH9.5 Novocastra, UK
GFAP rabbit IgG 1:1000 MW 10 min, TSC DakoCytomation, UK
GS goat IgG 1:500 PC, AR pH6.4 Millipore, UK
MHC II mouse IgG1κ 1:20 MW 10 min, TSC DakoCytomation, UK
NDRG2 goat IgG 1:75 PC, AS pH9.5 Santa Cruz, USA
MW:microwave; PC: pressure cooker; TSC: trisodium citrate buffer, pH6.5; MAR: Access Revelation pH6.4 (Menarini
Diagnostics, UK); AS: Access Super pH9.5 (Menarini Diagnostics, UK).
4.3. Quantitative Analysis of NDRG2
Assessment of NDRG2-specific immunoreactivity was performed by capturing bright-field
microscopic images in 3 adjacent 350 µm-wide cortical ribbons, consisting of contiguous fields to cover
the total cortical thickness through the apex of the gyrus, using a ×20 objective (Nikon Eclipse Ni-U
microscope, Nikon Instruments Europe BV, Amsterdam, Netherlands) and analysed using the Analysis
ˆD software (Olympus Biosystems, Watford, UK). The image was thresholded and the immunoreactive
area (%) of the field determined per total area examined.
4.4. Previously Assessed Astrocyte Markers and Age-Associated Pathology
Previous studies of the temporal cortex in the CFAS cohort using an identical approach have
determined the immunoreactive profile (% area immunoreactivity) of astrocytes (GFAP, EAAT2, GS),
microglia (CD68, MHC II) and AD pathology (Aβ, AT8) in 3 adjacent cortical ribbons [10,38,42].
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To assess the DNA damage response, the total number of γH2AX positive astrocyte nuclei was
quantitated using Analysis Dˆ software [38].
4.5. Statistical Analysis
As the data from all of the markers were positively skewed, non-parametric methods were used
for statistical analysis. Differences between astrocyte markers were compared using Friedman’s test.
For assessment in relation to BraakNFT stage, the caseswere grouped into entorhinal stages (Braak stages
0-II; 30 cases), limbic stages (Braak stages III-IV; 50 cases) and isocortical stages of tangle pathology
(Braak stages V-VI; 17 cases). Differences according to Braak group and to local plaque and tangle scores
were assessed by Kruskal–Wallis test, and significance of trend assessed using the Jonckheere–Terpstra
test (JT). Correlation analysis was performed using Spearman’s rank test. Statistical analyses were
performed using the statistical package SPSS (version 23, IBM, Armonk, NY, USA).
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